通过系统性审查和元分析预测头癌的短期治疗毒性
Marco A Mascarella1, Varun Vendra2, Khalil Sultanem3
1Department of Biomedical Sciences, Université de Montréal, Montreal, Quebec, Canada; Department of Otolaryngology, McGill University, Montreal, Quebec, Canada; Centre for Clinical Epidemiology, Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada.
Journal of geriatric oncology
|September 13, 2024
概括
头癌 (HNC) 患者的脆弱性显著增加了短期治疗毒性风险. 在接受前置手术的患者中,这种风险增加,这强调了HNC护理中脆弱性评估的重要性.
科学领域:
- 在瘤学瘤学.
- 老年病的医生 老年病的医生
- 公共卫生 公共卫生
背景情况:
- 脆弱性是头癌 (HNC) 患者不良结果的重要预测因素.
- 评估脆弱性对于管理治疗毒性和改善HNC患者预后至关重要.
研究的目的:
- 评估各种虚弱指标对HNC患者短期治疗毒性的预后意义.
- 确定脆弱性评估是否可以预测治疗意图的HNC治疗的患者的毒性.
主要方法:
- 一项对36项涉及292,560名HNC患者的观察性研究的系统综述和元分析.
- 评估常见的脆弱性指标,包括修改的脆弱性指数 (mFI),老年8 (G8),调整的临床组 (ACG),格罗宁根脆弱性指标 (GFI) 和综合老年评估 (CGA).
主要成果:
- 在HNC患者中,虚弱的总体患病率为7.5%.
- 虚弱与多个指标的短期治疗毒性显著增加有关 (ORs从2.60到3.43不等).
- 脆弱性和毒性之间的关联在接受前期手术的患者中比最终 (化疗) 放射治疗更为明显.
结论:
- 各种脆弱性指标始终确定HNC患者的短期治疗毒性风险较高.
- 脆弱性评估是预测HNC患者的毒性,特别是那些接受手术的患者的有价值的预后工具.
更多相关视频
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Hazard Ratio
96
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
96
Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Toxic Reactions: Overview
958
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
958


